{"id":62339,"date":"2025-12-11T07:05:47","date_gmt":"2025-12-11T06:05:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/"},"modified":"2025-12-11T07:05:47","modified_gmt":"2025-12-11T06:05:47","slug":"innate-pharma-releases-its-2026-financial-calendar","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/","title":{"rendered":"Innate Pharma Releases Its 2026 Financial Calendar"},"content":{"rendered":"<div>\n<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/immunotherapy?src=hash\" target=\"_blank\">#immunotherapy<\/a>&#8211;Regulatory News:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251210331629\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251210331629\/en\/1245155\/22\/INNATEvertnoirDS.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251210331629\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251210331629\/en\/1245155\/21\/INNATEvertnoirDS.jpg\"><\/a><\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<b>Innate<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) today released its 2026 financial calendar:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>March 26, 2026<\/b>: Publication of 2025 financial statements\n<\/li>\n<li>\n<b>May 13, 2026<\/b>: Publication of revenue and cash position for 1Q2026\n<\/li>\n<li>\n<b>May 21, 2026<\/b>: Annual General Shareholders Meeting\n<\/li>\n<li>\n<b>September 17, 2026<\/b>: Publication of half year financial statements\n<\/li>\n<li>\n<b>November 5, 2026<\/b>: Publication of revenue and cash position for 3Q2026\n<\/li>\n<\/ul>\n<p>\nAll financial reports are released before market opens CET.\n<\/p>\n<p>\nAll corporate information, such as the Company\u2019s financial statements and corporate presentations, is available on the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finnatepharma2021ir.q4web.com%2FEnglish%2Finvestors%2Foverview%2Fdefault.aspx&amp;esheet=54373140&amp;newsitemid=20251210331629&amp;lan=en-US&amp;anchor=Investors+section&amp;index=1&amp;md5=5078bbcd7868e9507378106e0664dce7\" rel=\"nofollow\" shape=\"rect\">Investors section<\/a> on the Company website.\n<\/p>\n<p>\n<b>About Innate Pharma<\/b>\n<\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.\n<\/p>\n<p>\nInnate Pharma is advancing a portfolio of differentiated potential first and\/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.\n<\/p>\n<p>\nInnate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.\n<\/p>\n<p>\nLearn more about Innate Pharma at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=54373140&amp;newsitemid=20251210331629&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=2&amp;md5=882cca2a721439128864b461a326f25e\" rel=\"nofollow\" shape=\"rect\">www.innate-pharma.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=54373140&amp;newsitemid=20251210331629&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=3df06b3e5e45306788eb4312153551bb\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FInnatePharma&amp;esheet=54373140&amp;newsitemid=20251210331629&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=e6651ca5b6e33f0e8603cc6c50fbe398\" rel=\"nofollow\" shape=\"rect\">X<\/a>.\n<\/p>\n<p>\n<b>Information about Innate Pharma shares<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>ISIN code<\/b><br \/><b>Ticker code<\/b><br \/><b>LEI<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421\n<\/p>\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA\n<\/p>\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Disclaimer on forward-looking information and risk factors<\/b>\n<\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cpotential,\u201d \u201cexpect\u201d \u201cshould,\u201d \u201cwill,\u201d or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s reliance on third parties to manufacture its product candidates, the Company\u2019s commercialization efforts and the Company\u2019s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=54373140&amp;newsitemid=20251210331629&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=5&amp;md5=c3fb1472a847ffe8a7fd2c15ab69dc23\" rel=\"nofollow\" shape=\"rect\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.\n<\/p>\n<p>\nIn light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.\n<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Innate Pharma<\/b><br \/>St\u00e9phanie Cornen<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;t&#111;&#x3a;&#115;&#x74;e&#112;&#x68;&#97;&#x6e;i&#x65;&#x2e;&#99;&#x6f;r&#x6e;e&#110;&#x40;&#105;&#x6e;n&#97;&#x74;&#101;&#x2d;p&#104;&#x61;&#114;&#x6d;a&#x2e;&#x66;&#114;\" rel=\"nofollow\" shape=\"rect\">&#115;&#x74;&#101;&#x70;&#104;&#x61;&#110;&#x69;&#101;&#x2e;&#99;&#x6f;r&#x6e;e&#x6e;&#64;&#x69;n&#x6e;a&#x74;e&#45;&#x70;&#104;&#x61;&#114;&#x6d;&#97;&#x2e;&#102;&#x72;<\/a>\n<\/p>\n<p>\n<b>Investor Relations<\/b><br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x69;n&#x76;&#x65;&#115;&#x74;o&#114;&#x73;&#64;&#105;&#x6e;n&#x61;&#x74;&#101;&#x2d;&#x70;&#104;&#x61;r&#109;&#x61;&#46;&#102;&#x72;\" rel=\"nofollow\" shape=\"rect\">inv&#101;&#115;&#116;&#x6f;&#x72;&#x73;&#x40;&#x69;&#x6e;nat&#101;&#45;&#112;&#104;&#x61;&#x72;&#x6d;&#x61;&#x2e;&#x66;r<\/a>\n<\/p>\n<p>\n<b>Medias<\/b><br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#x6f;:&#99;&#x6f;&#109;&#x6d;&#117;&#x6e;i&#x63;a&#116;&#x69;&#111;&#x6e;&#64;&#x69;n&#x6e;&#x61;&#116;&#x65;&#45;&#x70;h&#x61;r&#109;&#x61;&#46;&#x66;&#114;\" rel=\"nofollow\" shape=\"rect\">&#99;&#x6f;&#x6d;m&#117;&#x6e;i&#99;&#x61;&#x74;&#105;&#x6f;&#x6e;&#64;&#105;&#x6e;n&#97;&#x74;&#x65;&#45;&#x70;&#x68;a&#114;&#x6d;a&#46;&#x66;&#x72;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#immunotherapy&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62339","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Releases Its 2026 Financial Calendar - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Releases Its 2026 Financial Calendar - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#immunotherapy&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-11T06:05:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251210331629\/en\/1245155\/22\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Innate Pharma Releases Its 2026 Financial Calendar\",\"datePublished\":\"2025-12-11T06:05:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/\"},\"wordCount\":733,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251210331629\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/\",\"name\":\"Innate Pharma Releases Its 2026 Financial Calendar - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251210331629\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2025-12-11T06:05:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251210331629\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251210331629\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-releases-its-2026-financial-calendar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Releases Its 2026 Financial Calendar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Releases Its 2026 Financial Calendar - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Releases Its 2026 Financial Calendar - Pharma Trend","og_description":"MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#immunotherapy&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/","og_site_name":"Pharma Trend","article_published_time":"2025-12-11T06:05:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251210331629\/en\/1245155\/22\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Innate Pharma Releases Its 2026 Financial Calendar","datePublished":"2025-12-11T06:05:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/"},"wordCount":733,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251210331629\/en\/1245155\/22\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/","url":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/","name":"Innate Pharma Releases Its 2026 Financial Calendar - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251210331629\/en\/1245155\/22\/INNATEvertnoirDS.jpg","datePublished":"2025-12-11T06:05:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251210331629\/en\/1245155\/22\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251210331629\/en\/1245155\/22\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-releases-its-2026-financial-calendar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Releases Its 2026 Financial Calendar"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62339"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62339\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}